CN110386981A - 抗gitr抗体及其用途 - Google Patents

抗gitr抗体及其用途 Download PDF

Info

Publication number
CN110386981A
CN110386981A CN201810364111.9A CN201810364111A CN110386981A CN 110386981 A CN110386981 A CN 110386981A CN 201810364111 A CN201810364111 A CN 201810364111A CN 110386981 A CN110386981 A CN 110386981A
Authority
CN
China
Prior art keywords
antibody
amino acid
acid sequence
gitr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810364111.9A
Other languages
English (en)
Chinese (zh)
Inventor
翟天航
付凤根
黄威峰
刘军建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinda Biopharmaceutical (suzhou) Co Ltd
Innovent Biologics Suzhou Co Ltd
Original Assignee
Xinda Biopharmaceutical (suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinda Biopharmaceutical (suzhou) Co Ltd filed Critical Xinda Biopharmaceutical (suzhou) Co Ltd
Priority to CN201810364111.9A priority Critical patent/CN110386981A/zh
Priority to CN201980022627.8A priority patent/CN111918878B/zh
Priority to PCT/CN2019/083241 priority patent/WO2019201301A1/fr
Priority to TW108113605A priority patent/TWI743469B/zh
Publication of CN110386981A publication Critical patent/CN110386981A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201810364111.9A 2018-04-20 2018-04-20 抗gitr抗体及其用途 Pending CN110386981A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201810364111.9A CN110386981A (zh) 2018-04-20 2018-04-20 抗gitr抗体及其用途
CN201980022627.8A CN111918878B (zh) 2018-04-20 2019-04-18 抗gitr抗体及其用途
PCT/CN2019/083241 WO2019201301A1 (fr) 2018-04-20 2019-04-18 Anticorps anti-gitr et utilisation associée
TW108113605A TWI743469B (zh) 2018-04-20 2019-04-18 抗ｇｉｔｒ抗體及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810364111.9A CN110386981A (zh) 2018-04-20 2018-04-20 抗gitr抗体及其用途

Publications (1)

Publication Number Publication Date
CN110386981A true CN110386981A (zh) 2019-10-29

Family

ID=68239925

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810364111.9A Pending CN110386981A (zh) 2018-04-20 2018-04-20 抗gitr抗体及其用途
CN201980022627.8A Active CN111918878B (zh) 2018-04-20 2019-04-18 抗gitr抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980022627.8A Active CN111918878B (zh) 2018-04-20 2019-04-18 抗gitr抗体及其用途

Country Status (3)

Country Link
CN (2) CN110386981A (fr)
TW (1) TWI743469B (fr)
WO (1) WO2019201301A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022001189A1 (fr) * 2020-06-28 2022-01-06 东大生物技术(苏州)有限公司 Anticorps monoclonal anti-gitr et son utilisation médicale

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022205989A1 (en) * 2021-01-08 2023-07-27 Lanier Biotherapeutics, Inc. Neutralizing antibodies to il-17a, fusion proteins thereof, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3023438T3 (pl) * 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022001189A1 (fr) * 2020-06-28 2022-01-06 东大生物技术(苏州)有限公司 Anticorps monoclonal anti-gitr et son utilisation médicale

Also Published As

Publication number Publication date
WO2019201301A1 (fr) 2019-10-24
CN111918878B (zh) 2022-08-23
CN111918878A (zh) 2020-11-10
TWI743469B (zh) 2021-10-21
TW201946658A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
AU2017200281B2 (en) S100a4 antibodies and therapeutic uses thereof
CN110214154A (zh) 抗cd47抗体及其用途
EP3604338A1 (fr) Anticorps anti-ox40 et utilisation correspondante
WO2020151761A1 (fr) Anticorps bispécifique se liant à pd-l1 et ox40
WO2021259199A1 (fr) Anticorps anti-cd73 et son utilisation
KR20140027051A (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
WO2021254481A1 (fr) Anticorps anti-claudine 18.2 et son utilisation
TWI743469B (zh) 抗ｇｉｔｒ抗體及其用途
DK2984108T3 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
CN115368458A (zh) 抗cd73抗体及其应用
US20220127364A1 (en) Novel anti-pd-l1 antibody and uses thereof
WO2021175191A1 (fr) Anticorps anti-tim-3 et son utilisation
WO2023087016A1 (fr) Méthodes pour inverser la suppression immunitaire induite par treml1
JP2008056647A (ja) Ｆｃα／μレセプターに対する抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191029